Brief: AB Science: Masitinib Clinical Development In Sickle Cell Disease Among 19 Winning Projects Under RHU
27/11/2023 07:12
Nov 27 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE: THE CLINICAL DEVELOPMENT OF MASITINIB IN
SICKLE CELL
DISEASE IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL
FOR “HOSPITAL-INUVERSITY RESEARCH IN HEALTH (RHU)”
* THIS PROGRAM WILL FUND A MASITINIB PHASE 2 CLINICAL TRIAL
Source text for Eikon: ID:nGNE1V9vh4
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041